Medical condition
Flu
Flu is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- tislelizumab (TEVIMBRA) Antineoplastic and immunomodulating agents (L01)
- rasagiline (ALZIRAS) Nervous system (N04)
- pramipexole (APO-PRAMIPEXOLE) Nervous system (N04)
- pantoprazole (APO-PANTOPRAZOLE) Alimentary tract and metabolism (A02)
- influenza mrna vaccine (MCOMBRIAX) Antiinfectives for systemic use (J07)
- voriconazole (VFEND) Antiinfectives for systemic use (J02)
- teriflunomide (APO-TERIFLUNOMIDE) Antineoplastic and immunomodulating agents (L04)
- posaconazole (PHARMACOR POSACONAZOLE) Antiinfectives for systemic use (J02)
- peramivir (ALPIVAB) Antiinfectives for systemic use (J05)
- opicapone (ONGENTYS) Nervous system (N04)
- levodopa (CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)) Nervous system (N04)
- leflunomide (APO-LEFLUNOMIDE) Antineoplastic and immunomodulating agents (L04)
Latest Flu news
Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response
Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.
Moderna's mRNA-1083 Phase 3 shows stronger flu and COVID immune responses
Moderna's mRNA-1083 posted positive Phase 3 results in adults 50 and older, meeting primary endpoints with stronger immune responses against influenza and SARS-CoV-2 than licensed comparators. The readout strengthens the case for a combined flu-COVID vaccine, but regulatory questions about the separate flu vaccine filing remain relevant for BD teams and investors.
Genentech's Strategy to Influence Pharma Reforms
Genentech is actively soliciting research to mitigate the impact of proposed pharmaceutical reforms in Washington. This article explores the implications for the industry.
FDA in Flux: May 2026 Drug Approvals Update
This newsletter covers the recent FDA drug approvals and their potential impact on the pharmaceutical landscape. Stay informed on the latest regulatory changes.
Roche's Licensing Deal for Generic Xofluza: Implications and Insights
Roche has signed a licensing deal for generic Xofluza with the Medicines Patent Pool, impacting 129 countries. This article explores the implications for pharma teams and investors.
Sprout Pharmaceuticals Addyi (Flibanserin) Maker Named Top 10 Most Influential Health Company by TIME 2026
Sprout Pharmaceuticals, maker of Addyi (flibanserin), joins TIME's 10 most influential health companies of 2026 following FDA approval expansion and growth.
FDA Approves FluGuard+ Vaccine: Enhanced Protection Against Emerging Flu
The FDA has approved FluGuard+, a new vaccine designed to provide enhanced protection against emerging flu strains, improving public health outcomes.
FDA Approves Ritempro: New Parkinson's Disease Motor Fluctuations Treatment
Ritempro has received FDA approval as a novel treatment for motor fluctuations in Parkinson's disease, promising improved management for patients.